Impact of Disease‐Specific Treatment and Non‐Selective Beta Blockers on Risk of PVT in Cirrhotic Patients With HCV or PBC

Key Points

• This research aims to evaluate the relationship between disease-specific treatments and the risk of portal vein thrombosis (PVT) in cirrhotic patients with HCV or PBC.
• Analyzed two large samples of cirrhotic patients with HCV or PBC.
• Examined the association between disease-specific treatments and PVT risk.
• Assessed the impact of non-selective beta blocker (NSBB) treatment on PVT risk across different patient statuses.
• Disease-specific treatments did not show any correlation with PVT risk.
• Patients treated with NSBB had over two times the risk of developing PVT in both patient samples.